Biocon product launch announcements

Product LaunchBiocon Ltd BIOCONAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Biocon Product Launch

Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.

Product LaunchBiocon Ltd BIOCONAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Biocon Product Launch

Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.

Value

₹46,500 Cr